Will Anti-Obesity Drugs Disrupt the MedT...

Live from Morgan Stanley’s TMT conference, our panel break down where AI is already delivering real returns—and where rapid advances are raising new risks.Read more insights from Morgan Stanley.----- Transcript -----Michelle Weaver: Welcome to Thoughts on the Market. I'm Michelle ... Show More

Our Deputy Global Head of Research Michael Zezas and Head of Public Policy Research Ariana Salvatore assess the potential market outcomes of the Middle East conflict, weighing its possible duration and economic impact.Read more insights from Morgan Stanley.----- Transcript -----M ... Show More

Our Hong Kong/China Transportation & Infrastructure Analyst Qianlei Fan discusses how China’s travel industry is shifting from a post-pandemic rebound to a multi-year expansion.Read more insights from Morgan Stanley.----- Transcript -----Welcome to Thoughts on the Market. I’m Qia ... Show More

It’s become a multibillion-dollar business: weight loss drugs. Demand is high, as is the cost. How did medications like Ozempic, Wegovy, Mounjaro and Zepbound become so popular and so profitable? And what kind of impact might they have on the future of food and healthcare? Dr. Sa ... Show More

A discussion of claims that obesity is mostly due to genetics. (1:30) Should a pharmaceutical company be for profit? (7:38) What is Big Pharma's motivation behind these claims? (10:09) What does obesity contribute to? (15:52) Is capitalism to blame? (21:14) Lifestyle is EVERYTHIN ... Show More

Over 1 billion people worldwide are obese, according to the World Health Organization. If current trends continue, half the world could be obese or overweight by 2035. The WHO refers to it as an epidemic. Recent data shows that over 40% of Americans are living with obesity. But o ... Show More

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ... Show More

In today's episode of the podcast, I interview Dr. Rocio Salas-Whalen, owner of New York Endocrinology on Park Avenue. Dr. Salas-Whalen has deep expertise in diabetes, metabolism, obesity, thyroid abnormalities and other endocrine disorders. She completed her internal medicine re ... Show More

CardioNerds Dr. Rick Ferraro (CardioNerds Academy House Faculty and Cardiology Fellow at JHH), Dr. Gurleen Kaur (Director of the CardioNerds Internship and Internal Medicine resident at BWH), and Dr. Alli Bigeh (Cardiology Fellow at the Ohio State) as they discuss the growing obe ... Show More

<p>Over the last 30 years, fatness has been defined as a risk factor for disease, then a disease in itself, then a global epidemic. What caused this rapid shift? Who’s gonna join our group of B-roll vigilantes? And did we just hear Morgan Freeman?</p><p>Support us:</p><ul><li><a ... Show More

How much harm has been done by decades of governments investing too little? Is buy-now-pay-later causing misery or joy for young shoppers? Are supermarkets cutting prices fast enough? Is Novo Nordisk’s anti obesity wonder drug Semaglutide the most important pharmaceutical discove ... Show More

<p>For nearly four decades, Americans have heard a simple story about health, longevity and obesity. This week, we learn it&apos;s a little more complicated. <br/><br/>Thanks to Katherine Flegal, Paul Campos, Jeff Hunger and Jason Salemi for helping us research and fact-check thi ... Show More